TY  - JOUR
AU  - Ferrer, Irene
AU  - Quintanal-Villalonga, Alvaro
AU  - Molina-Pinelo, Sonia
AU  - Garcia-Heredia, Jose Manuel
AU  - Perez, Marco
AU  - Suárez, Rocío
AU  - Ponce-Aix, Santiago
AU  - Paz Ares , Luis Gonzaga
AU  - Carnero, Amancio
PY  - 2018
DO  - 10.1186/s13046-018-0871-7
SN  - 1756-9966
UR  - http://hdl.handle.net/20.500.12105/6597
AB  - BACKGROUND: The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase...
LA  - eng
PB  - BioMed Central (BMC)
KW  - Biomarkers
KW  - Lung cancer
KW  - PDZK1IP1
KW  - Treatment efficacy
KW  - Adenocarcinoma
KW  - Adult
KW  - Aged
TI  - MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
TY  - journal article
ER  -